Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

March 15, 2026

Study Completion Date

February 15, 2031

Conditions
Multi Vessel Coronary Artery Disease
Interventions
DEVICE

CABG

"Elective, coronary artery bypass (CABG) surgery. Each study subject will receive an left internal mammary artery (LIMA) conduit to the left anterior descending (LAD) coronary artery. Patients with uncompromised saphenous veins will receive a SVG to the LCX or RCA and the XABG to the remaining territory. Patients with compromised arterial and/or saphenous veins, (i.e., no-vein patients), will receive one XABG to the LCX or RCA to achieve incomplete revascularization."

Trial Locations (4)

Unknown

UZ Leuven, Leuven

Vilnius University Hospital Santaros Klinikos, Vilnius

John Paul II Hospital Krakow, Krąków

Medicover Hospital, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Xeltis

INDUSTRY